Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
NaBC1 CRISPR/Cas9 KO Plasmid (h): sc-405950
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- NaBC1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the NaBC1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: NaBC1 Antibody (B-12): sc-393808
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NaBC1 CRISPR/Cas9 KO Plasmid (h) | sc-405950 | 20 µg | $397.00 |
Overview
BCAS1 (brain enriched myelin associated protein 1), also referred to as NaBC1, is a human gene with enriched expression in the central nervous system and is widely used as a marker of oligodendrocyte lineage cells and active myelination. Its expression is associated with oligodendrocyte differentiation and myelin formation programs, linking it to cellular processes that govern axon insulation and white matter maturation. Altered BCAS1/NaBC1 expression has been reported in studies of demyelinating and neurodegenerative contexts, supporting its relevance for investigating mechanisms of myelin loss and repair. As a lineage-associated factor, BCAS1 provides an entry point for dissecting transcriptional and proteostatic networks that shape oligodendrocyte state transitions.
NaBC1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the BCAS1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the BCAS1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the BCAS1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish NaBC1 protein expression.
This CRISPR knockout system enables efficient generation of BCAS1-deficient cell models for investigation of NaBC1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting BCAS1 exon(s) critical for NaBC1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple BCAS1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by NaBC1 CRISPR/Cas9 KO Plasmid (h) and NaBC1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the BCAS1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by NaBC1 HDR Plasmid (h) and NaBC1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by BCAS1 homology arms to support homology-directed repair at defined BCAS1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.